Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emavusertib open-label phase 1/2 trial in relapsed or refractory primary central nervous system lymphoma
2024-513312-95-00Phase 2Authorised
- Sponsor
- Curis, Inc.
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of emavusertib and ibrutinib in primary central nervous system lymphoma (PCNSL) and hematopoietic malignancies (3 arms), sponsored by Curis, Inc. Planned start May 2023; status: authorised.
02
Drugs
emavusertibibrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)hematopoietic malignancies
Beyond the preview
Go deeper on 2024-513312-95-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513312-95-00.